Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. XYZResearch published a report for global Breast Cancer Predictive Genetic Testing market in this environment.
In terms of revenue, this research report indicated that the global Breast Cancer Predictive Genetic Testing market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Breast Cancer Predictive Genetic Testing industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Roche aims at producing XX Breast Cancer Predictive Genetic Testing in 2020, with XX % production to take place in global market, Thermo Fisher Scientific accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Breast Cancer Predictive Genetic Testing Market by XYZResearch Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Breast Cancer Predictive Genetic Testing Market?
Roche
Thermo Fisher Scientific
PerkinElmer
Quest Diagnostics
Myriad Genetics
Iverson Genetics
Cancer Genetics
OncoCyte Corporation
NeoGenomics
Invitae
...
Major Type of Breast Cancer Predictive Genetic Testing Covered in XYZResearch report:
High Penetrant Genes
Intermediate Penetrant Genes
Low Penetrant Genes
Application Segments Covered in XYZResearch Market
Hospitals
Clinics
Other
For any other requirements, please feel free to contact us and we will provide you customized report.
Request Sample 
Request Discount 
Inquire Before BuyTable of Contents
Global Breast Cancer Predictive Genetic Testing Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 High Penetrant Genes -Product Introduction and Major Manufacturers
1.1.2 Intermediate Penetrant Genes -Product Introduction and Major Manufacturers
1.1.3 Low Penetrant Genes -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Breast Cancer Predictive Genetic Testing Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)
3 Regional Market Analysis
3.1 China Breast Cancer Predictive Genetic Testing Market
3.1.1 Top Companies leading Breast Cancer Predictive Genetic Testing Development in China (2015-2020)
3.1.2 Sales Value of Major Company in China Market (2015-2020)
3.1.3 China Breast Cancer Predictive Genetic Testing Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2015-2026)
3.2 EU Breast Cancer Predictive Genetic Testing Market
3.2.1 Top Companies leading Breast Cancer Predictive Genetic Testing Development in EU (2015-2020)
3.2.2 Sales Value of Major Company in EU Market (2015-2020)
3.2.3 EU Breast Cancer Predictive Genetic Testing Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2015-2026)
3.3 USA Breast Cancer Predictive Genetic Testing Market
3.3.1 Top Companies leading Breast Cancer Predictive Genetic Testing Development in USA (2015-2020)
3.3.2 Sales Value of Major Company in USA Market (2015-2020)
3.3.3 USA Breast Cancer Predictive Genetic Testing Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2015-2026)
3.4 Japan Breast Cancer Predictive Genetic Testing Market
3.4.1 Top Companies leading Breast Cancer Predictive Genetic Testing Development in Japan (2015-2020)
3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
3.4.3 Japan Breast Cancer Predictive Genetic Testing Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2015-2026)
3.5 India Breast Cancer Predictive Genetic Testing Market
3.5.1 Top Companies leading Breast Cancer Predictive Genetic Testing Development in India (2015-2020)
3.5.2 Sales Value of Major Company in India Market (2015-2020)
3.5.3 India Breast Cancer Predictive Genetic Testing Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2015-2026)
3.6 Southeast Asia Breast Cancer Predictive Genetic Testing Market
3.6.1 Top Companies leading Breast Cancer Predictive Genetic Testing Development in Southeast Asia (2015-2020)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
3.6.3 Southeast Asia Breast Cancer Predictive Genetic Testing Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
3.7 South America Breast Cancer Predictive Genetic Testing Market
3.7.1 Top Companies leading Breast Cancer Predictive Genetic Testing Development in South America (2015-2020)
3.7.2 Sales Value of Major Company in South America Market (2015-2020)
3.7.3 South America Breast Cancer Predictive Genetic Testing Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2015-2026)
4 Value Chain (Impact of COVID-19)
4.1 Breast Cancer Predictive Genetic Testing Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Breast Cancer Predictive Genetic Testing Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2026)
5.1 Global Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2021-2026)
5.2 Global Breast Cancer Predictive Genetic Testing Sales Value and Growth Rate (2021-2026)
6 Breast Cancer Predictive Genetic Testing Competitive Analysis
6.1 Roche
6.1.1 Roche Company Profiles
6.1.2 Roche Product Introduction
6.1.3 Roche Breast Cancer Predictive Genetic Testing Production, Revenue (2015-2020)
6.1.4 SWOT Analysis
6.2 Thermo Fisher Scientific
6.2.1 Thermo Fisher Scientific Company Profiles
6.2.2 Thermo Fisher Scientific Product Introduction
6.2.3 Thermo Fisher Scientific Breast Cancer Predictive Genetic Testing Production, Revenue (2015-2020)
6.2.4 SWOT Analysis
6.3 PerkinElmer
6.3.1 PerkinElmer Company Profiles
6.3.2 PerkinElmer Product Introduction
6.3.3 PerkinElmer Breast Cancer Predictive Genetic Testing Production, Revenue (2015-2020)
6.3.4 SWOT Analysis
6.4 Quest Diagnostics
6.4.1 Quest Diagnostics Company Profiles
6.4.2 Quest Diagnostics Product Introduction
6.4.3 Quest Diagnostics Breast Cancer Predictive Genetic Testing Production, Revenue (2015-2020)
6.4.4 SWOT Analysis
6.5 Myriad Genetics
6.5.1 Myriad Genetics Company Profiles
6.5.2 Myriad Genetics Product Introduction
6.5.3 Myriad Genetics Breast Cancer Predictive Genetic Testing Production, Revenue (2015-2020)
6.5.4 SWOT Analysis
6.6 Iverson Genetics
6.6.1 Iverson Genetics Company Profiles
6.6.2 Iverson Genetics Product Introduction
6.6.3 Iverson Genetics Breast Cancer Predictive Genetic Testing Production, Revenue (2015-2020)
6.6.4 SWOT Analysis
6.7 Cancer Genetics
6.7.1 Cancer Genetics Company Profiles
6.7.2 Cancer Genetics Product Introduction
6.7.3 Cancer Genetics Breast Cancer Predictive Genetic Testing Production, Revenue (2015-2020)
6.7.4 SWOT Analysis
6.8 OncoCyte Corporation
6.8.1 OncoCyte Corporation Company Profiles
6.8.2 OncoCyte Corporation Product Introduction
6.8.3 OncoCyte Corporation Breast Cancer Predictive Genetic Testing Production, Revenue (2015-2020)
6.8.4 SWOT Analysis
6.9 NeoGenomics
6.9.1 NeoGenomics Company Profiles
6.9.2 NeoGenomics Product Introduction
6.9.3 NeoGenomics Breast Cancer Predictive Genetic Testing Production, Revenue (2015-2020)
6.9.4 SWOT Analysis
6.10 Invitae
6.10.1 Invitae Company Profiles
6.10.2 Invitae Product Introduction
6.10.3 Invitae Breast Cancer Predictive Genetic Testing Production, Revenue (2015-2020)
6.10.4 SWOT Analysis
7 Conclusion
| Price : US$ 3500 | Date : Apr 2024 |
| Category : Electronics | Pages : 124 |
| Price : US$ 3500 | Date : Apr 2024 |
| Category : Manufacturing and Construction | Pages : 115 |
| Price : US$ 3500 | Date : Apr 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 125 |
| Price : US$ 3500 | Date : Apr 2024 |
| Category : Manufacturing and Construction | Pages : 154 |
| Price : US$ 3500 | Date : Apr 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 132 |
We will be happy to help you find what you need. Please call us or write to us:
Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).
This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection
